Literature DB >> 25433998

Involvement of p29/SYF2/fSAP29/NTC31 in the progression of NSCLC via modulating cell proliferation.

Yifei Liu1, Tingting Ni2, Qun Xue3, Liting Lv2, Buyou Chen2, Xuefan Cui4, Yuan Cui3, Yuchan Wang1, Guoxin Mao5, Lili Ji6.   

Abstract

p29, also known as SYF2/fSAP29/NTC31, is a protein associated with chromatin and involved in DNA damage response, cell cycle arrest and pre-mRNA splicing. In p29-depleted cells, DNA replication was reduced and cell population in G1 phase increased. In this study, we investigated the potential role of p29 in the regulation of non-small cell lung cancer (NSCLC) progression. Western blot and immunohistochemistry staining showed that p29 was up-regulated in clinical NSCLC tissues compared with adjacent non-cancerous tissues, and the expression of p29 had a positive correlation with clinical stage and histological differentiation, as well as expression of Ki-67, a proliferating marker. Kaplan-Meier analysis indicated that patients with high level of p29 expression had poor overall survival. In addition, small interfering RNA of p29 was performed, and the effects on NSCLC growth were examined. Interference of p29 blocked S phase entry, inhibited proliferation of A549 cells and up-regulated level of p21 expression. Taken together, these results suggested that p29 might contribute to the progression of NSCLC by enhancing cell proliferation, implicating that targeting p29 might provide beneficial effects on the clinical therapy of NSCLC.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  NSCLC; Prognosis; Proliferation; p29/SYF2

Mesh:

Substances:

Year:  2014        PMID: 25433998     DOI: 10.1016/j.prp.2014.07.013

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.

Authors:  Jie Chen; Jun Gu; Jian Feng; Yifei Liu; Qun Xue; Tingting Ni; Zhiwen Wang; Liangliang Jia; Guoxin Mao; Lili Ji
Journal:  Tumour Biol       Date:  2015-10-17

2.  Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.

Authors:  Shusen Zhang; Weidong Shi; Yuyan Chen; Zhiwei Xu; Jia Zhu; Tingting Zhang; Wei Huang; Runzhou Ni; Cuihua Lu; Xiubing Zhang
Journal:  Mol Cell Biochem       Date:  2015-08-11       Impact factor: 3.396

3.  Genome-wide identification and functional analysis of the splicing component SYF2/NTC31/p29 across different plant species.

Authors:  Yuan Tian; Mo-Xian Chen; Jing-Fang Yang; H H K Achala; Bei Gao; Ge-Fei Hao; Guang-Fu Yang; Zhi-Yong Dian; Qi-Juan Hu; Di Zhang; Jianhua Zhang; Ying-Gao Liu
Journal:  Planta       Date:  2018-10-13       Impact factor: 4.116

4.  Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer.

Authors:  Feng Shi; Feng-Feng Cai; Lu Cai; Xiao-Yan Lin; Wei Zhang; Qin-Qin Wang; Yu-Jie Zhao; Qi-Chao Ni; Hua Wang; Zhi-Xian He
Journal:  Oncotarget       Date:  2017-05-23

5.  Single-Cell RNA-Seq Analysis of Cells from Degenerating and Non-Degenerating Intervertebral Discs from the Same Individual Reveals New Biomarkers for Intervertebral Disc Degeneration.

Authors:  Hosni Cherif; Matthew Mannarino; Alain Sarabia Pacis; Jiannis Ragoussis; Oded Rabau; Jean A Ouellet; Lisbet Haglund
Journal:  Int J Mol Sci       Date:  2022-04-03       Impact factor: 5.923

6.  Genome-wide comparison and in silico analysis of splicing factor SYF2/NTC31/p29 in eukaryotes: Special focus on vertebrates.

Authors:  Bao-Xing Huang; Zi-Chang Jia; Xue Yang; Chao-Lin Cheng; Xiao-Rong Liu; Jianhua Zhang; Mo-Xian Chen; Jing-Fang Yang; Yun-Sheng Chen
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

7.  OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations.

Authors:  Loris Mularoni; Radhakrishnan Sabarinathan; Jordi Deu-Pons; Abel Gonzalez-Perez; Núria López-Bigas
Journal:  Genome Biol       Date:  2016-06-16       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.